Sanara MedTech reports Q4 prelim net revenue up 45-48% YoY; FY up 32-33%

Sanara MedTech Inc.

2024-FY EPS reported -$1.14 revenue$86,672,425

Q4 2024 net revenue expected $25.7M-$26.2M, a 45-48% increase YoY.
Full year 2024 net revenue expected $86.0M-$86.5M, up 32-33% YoY.
BIASURGE sales benefited from ~$1.8M in temporary demand due to hurricane-related IV fluid shortages; expects normalization in Q1 2025.
Cash at Dec 31, 2024: $15.9M; debt $30.5M; $24.5M available borrowing capacity.
Appointed Keith Myers (former LHC Group CEO) to Board on Oct 4, 2024; filed 11 provisional patent applications in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.